How big is Sunshine Biopharma, Inc.?

As of Jun 18, Sunshine Biopharma, Inc. has a market capitalization of 6.70 million, with net sales of 36.23 million and a net profit of -5.03 million over the last four quarters. The company reported shareholder's funds of 23.50 million and total assets of 30.56 million as of Dec 24.

Market Cap: As of Jun 18, Sunshine Biopharma, Inc. has a market capitalization of 6.70 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Sunshine Biopharma reported net sales of 36.23 million and a net profit of -5.03 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 23.50 million and total assets of 30.56 million.

What does Sunshine Biopharma, Inc. do?

Sunshine Biopharma, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $9 million and a net loss of $1 million as of March 2025. The company has a market cap of $6.70 million and key metrics indicating it is currently loss-making.

Overview:<BR>Sunshine Biopharma, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 9 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -1 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 6.70 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.35 <BR>Return on Equity: -22.16% <BR>Price to Book: 0.29<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Should I buy, sell or hold Sunshine Biopharma, Inc.?

Is Sunshine Biopharma, Inc. overvalued or undervalued?

As of February 9, 2023, Sunshine Biopharma, Inc. is considered risky and overvalued due to significant losses and unfavorable valuation metrics, with a year-to-date return of -51.0% compared to the S&P 500's 12.22%.

As of 9 February 2023, the valuation grade for Sunshine Biopharma, Inc. has moved from does not qualify to risky, indicating increased caution regarding its financial health. The company appears to be overvalued given its significant losses and negative return metrics. Key ratios include a Price to Book Value of 0.30, an EV to EBIT of 0.18, and an EV to EBITDA of 0.19, all of which suggest that the market is not valuing the company favorably compared to its peers.<BR><BR>In comparison to its peers, Sunshine Biopharma's valuation metrics are less favorable; for instance, Cyclerion Therapeutics, Inc. has an EV to EBITDA of -1.2082, while Blue Water Biotech, Inc. stands at -1.3625. The company's stock has significantly underperformed against the S&P 500, with a year-to-date return of -51.0% compared to the S&P 500's 12.22%, reinforcing the notion that Sunshine Biopharma is overvalued in the current market context.

Is Sunshine Biopharma, Inc. technically bullish or bearish?

As of August 29, 2025, Sunshine Biopharma, Inc. has shifted to a mildly bearish trend, indicated by bearish daily moving averages and monthly Bollinger Bands, despite some mildly bullish signals from MACD and KST, while significantly underperforming the S&P 500 with a year-to-date return of -51.0%.

As of 29 August 2025, the technical trend for Sunshine Biopharma, Inc. has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating bearishness and a monthly Bollinger Bands signal showing mildly bearish conditions. While the MACD and KST are mildly bullish on both weekly and monthly time frames, the overall trend reflects weakness. The stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -51.0% versus the S&P 500's 12.22%.